We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Dialysis wars

4 May 2005 By Marianne Brun-Rovet

The deal has industrial logic, beefing up the German group s presence in US dialysis. But at 17 times operating profit, it won’t come cheap. The alldebt financing may help make the numbers work. But it will leave Fresenius very highly leveraged. The deal has industrial logic,beefing up the German group s presence in US dialysis. But at 16 times operating profits, it won’t come cheap. The alldebt financing may help make the numbers work. But it will leave Fresenius very highly leveraged.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)